1. Home
  2. FRHC vs GKOS Comparison

FRHC vs GKOS Comparison

Compare FRHC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Freedom Holding Corp.

FRHC

Freedom Holding Corp.

N/A

Current Price

$157.13

Market Cap

10.3B

Sector

Finance

ML Signal

N/A

Logo Glaukos Corporation

GKOS

Glaukos Corporation

N/A

Current Price

$238.06

Market Cap

9.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FRHC
GKOS
Founded
N/A
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.3B
9.7B
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
FRHC
GKOS
Price
$157.13
$238.06
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
★ $243.85
AVG Volume (30 Days)
95.9K
★ 1.5M
Earning Date
11-16-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 79.29
N/A
EPS
★ 1.28
N/A
Revenue
★ $2,191,291,000.00
$507,442,000.00
Revenue This Year
N/A
$53.82
Revenue Next Year
N/A
$28.56
P/E Ratio
$121.38
★ N/A
Revenue Growth
6.86
★ 32.33
52 Week Low
$107.98
$93.96
52 Week High
$190.60
$255.19

Technical Indicators

Market Signals
Indicator
FRHC
GKOS
Relative Strength Index (RSI) 40.36 60.24
Support Level $138.43 $147.72
Resistance Level $169.92 $255.19
Average True Range (ATR) 11.72 11.87
MACD -2.42 -1.86
Stochastic Oscillator 38.42 48.42

Price Performance

Historical Comparison
FRHC
GKOS

About FRHC Freedom Holding Corp.

Freedom Holding Corp is a holding company with reportable segments into the following four segments: Brokerage, Banking, Insurance, and Other. The majority of revenue is from the Banking segment. Banking segment consists of the operations of Freedom Bank KZ and Freedom Bank TJ. Geographically, operates in Kazakhstan, Armenia, Cyprus, the USA, and others, with maximum revenue from Kazakhstan.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: